49
In band
Moving averages
SMA 200$2.31-48.05%
Company profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
SectorHealthcare
IndustryBiotechnology
Market cap$71.63M
P/E ratio8.79
EPS$0.14
Beta1.484
Dividend yield0.00%
52-week high$3.08
52-week low$1.08
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 52
VRTX
Vertex Pharmaceuticals Inc
RSI 64
CRSP
CRISPR Therapeutics AG
RSI 54
IOVA
Iovance Biotherapeutics Inc
RSI 66
MRNA
Moderna Inc
RSI 67
VKTX
Viking Therapeutics Inc
RSI 49
SRPT
Sarepta Therapeutics Inc
RSI 67
EDIT
Editas Medicine Inc
RSI 52
NVAX
Novavax Inc
RSI 72
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 44
RSI alerts for SPRO
Get an email the moment Spero Therapeutics Inc crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 16 August 2026 at 3:33 AM EDT